Role of Glycation and Inflammation in Acute Ischemic Heart Disease (AGLIANICO)

GEK Srl

Status: Terminated

Conditions: Inflammation; Heart Inflammation; Myocardial Infarction; Heart Injuries; Glycation End Products, Advanced

Treatments: Diagnostic Test: BAFF and MGO

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT05112731

2021AGLIANICO

Details and patient eligibility

About

This study requires the consecutive enrollment of 60 patients following the first event of acute myocardial infarction, evaluating B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting (pre-reperfusion) and 3 months after reperfusion.

Full description

This study requires the consecutive enrollment of 60 patients at admission for first acute myocardial infarction. At enrollment, before reperfusion, a blood sample is obtained to measure B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting. This measure is then repeated at follow-up visit 3 months after reperfusion. The aim of the study is to identify specific subsets of patients and evaluate biomarkers variations.

Enrollment: 16 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• hospitalization for first myocardial infarction (STEMI or NSTEMI)
• age between 18 and 80

Exclusion criteria

• uncompensated T2DM (HbA1c >53mmol/mol)
• use of anti-CD20 treatment
• chronic anti-inflammatory treatment for autoimmune disease (i.e. DMARDs, high dose FANS, cortisonic drugs)

Trial design

16 participants in 1 patient group

First Ischemic Cardiac Event

Description:

Measurement of BAFF and MGO at hospitalization (before reperfusion) and after 3 months during follow-up

Treatment:

Diagnostic Test: BAFF and MGO